Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ended
Participants planned
30
Countries
1
Sites
3
allergic asthma
Key facts
- Sponsor
- Jasper Therapeutics Inc.
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Respiratory Tract Diseases [C08]
- Trial duration
- completed 5 Dec 2024
- Decision date (initial)
- 2024-10-24
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
allergic asthma
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 21.1 | LLT | 10001705 | Allergic asthma | 10038738 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Jasper Therapeutics Inc.
- Sponsor organisation
- Jasper Therapeutics Inc.
- Address
- 2200 Bridge Parkway Suite 102
- City
- Redwood City
- Postcode
- 94065-1186
- Country
- United States
Scientific contact point
- Organisation
- Jasper Therapeutics Inc.
- Contact name
- Edwin Tucker
Public contact point
- Organisation
- Jasper Therapeutics Inc.
- Contact name
- Patricia Carlos
Locations
1 EU/EEA country · 3 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Germany | Ended | 8 | 3 |
| Rest of world
Canada
|
— | 22 | — |
Investigational sites
Velocity Clinical Research Grosshansdorf GmbH
N/A, Woehrendamm 80, 22927, Grosshansdorf
The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM
N/A, Nikolai-Fuchs-Strasse 1, Gross Buchholz, Hanover
IKF Pneumologie GmbH & Co. KG
Clinical Research Centre, Respiratory Medicine, Helix Medical Excellence Center, Haifa-Allee 24, Bretzenheim, Mainz
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-07-18 | Germany | Acceptable 2024-10-23
|
2024-10-24 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2024-11-07 | Germany | Acceptable 2024-10-23
|
2024-11-07 |